Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

American Journal of Medicine

Volumn 101, Issue 5, 1996, Pages 488-501

  Tucci, Joseph R ^a   Tonino, Richard P ^b   Emkey, Ronald D ^c   Peverly, Christine A ^d   Kher, Uma ^d   Santora II, Arthur C ^d  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c READING HOSPITAL AND MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RADIODENSITOMETRY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE RESORPTION; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030278360     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00282-3     Document Type: Article

References (43)

1. Riggs BL, Melton LJ. Involutional osteoporosis. NEJM. 1986; 314: 1676-1686.
2. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650.
3. Parfitt AM. Pathophysiology of bone fragility. Proc Fourth International Symposium on Osteoporosis. Hong Kong. 1993;S43:164-166.
4. Osteoporosis: Who should be treated? Proceedings of a symposium. Am J Med. 1995;98(2A).
5. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif. Tissue Int. 1993;53:283-288.
6. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int. 1993; (suppl 3): S7-12.
7. Chesnut CH, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporosis Int. 1993;3(suppl. 3):S17-19.
8. Chesnut C, McClung MR, Ensrud K, et al. Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
9. Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos Int. 1993; (Suppl 3):21-27.
10. Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther. 1976;20:593-604.
11. Kanis JA, Alexeeva L, Bonjour JP, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int. 1994;4:368-381.
12. Liberman UA, Weiss, SR, Broll J, et al. Effect of three years' treatment with oral alendronate on fracture incidence in women with postmenopausal osteoporosis. NEJM. 1995;333:1437-1443.
13. Masud T, Langley S, Wiltshire P, Doyle DV, Spector TD. Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis. Br Med J. 1993;3071:172-173.
14. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
15. Capizzi T, Survill TT, Heyse JF, Malani H. An empirical and simulated comparison of some tests for detecting progressiveness of response with increas-ing doses of a compound. Biometrical Journal. 1992;34:275-289.
16. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41:361-372.
17. Lufkin EG, Argueta R, Whitaker MD et al. Pamidronate: an unrecognized problem gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
18. Seedor JG, Quartuccio HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991;6:339-346.
19. Thompson DD, Seedor JG, Quartuccio H, et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res. 1992;7:951-960.
20. Seedor JG, Balena R, Masarachia P, Rodan GA. Comparison of the therapeutic potencies of two bisphosphonates. Bone. 1992;13 (Suppl. 1):S116.
21. Toolan BC, Shea M, Myers ER, et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res. 1992;7:1399-1406.
22. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577-2586.
23. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833-1837.
24. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res. 1994;9:1515-1523.
25. Parfitt AM. The coupling of bone formation to bone resorption. A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Rel Res. 1982;4:16.
26. Valkema R, Vismans F-JFE, Papapoulos SE, et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989;5:183-192.
27. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178-208.
28. Parfitt AM. Morphologic basis of bone mineral measurements: transient and steady-state effects of treatment in osteoporosis. Miner Electrolyte Metab. 1980;4:273-287.
29. Reid I, Wattie D, Evans M, et al. Continuous therapy with pamidronate, a potent bisphosphonate in postmenopausal osteoporosis. J. Clin Endocrinol and Metab. 1994;79:1595-1599.
30. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993; 95:557-567.
31. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet. 1990;336: 265-269.
32. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
33. Kleerckoper M, Nelson DA, Peterson EL, Tilley BC. Outcome variable in osteoporosis trials. Bone. 1992;13:529-334.
34. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etridronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM 1990;322:1265-1271.
35. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
36. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab. 1991;72:367-373.
37. Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab. 1990;71:836-841.
38. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79:1693-1700.
39. Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 1988;82:1268-1274.
40. Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1991;41:289-318.
41. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the fracture intervention trial. Osteoporosis Int. 1993; (suppl 3):S29-39.
42. Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int. 1986;38:3-8.
43. Overgaard K, Hansen MA, Jensin SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J. 1992;305:556-561.